nitrendipine
Isolated Systolic Hypertension
KU LeuvenPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
17 Active assets in the Isolated Systolic Hypertension cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hydrochlorothiazide Yuhan Corporation | Phase 4 | BBB |
AMLODIPINE Yuhan Corporation | Phase 4 | BBB |
VALSARTAN ARKAY Therapeutics | Phase 4 | BB |
Phentermine VIVUS LLC | Phase 4 | BB |
Dapagliflozin University of Campinas, Brazil | Phase 4 | BB |
View all 44 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →